-+ 0.00%
-+ 0.00%
-+ 0.00%

Bearish: This Analyst Is Revising Their Jeena Sikho Lifecare Limited (NSE:JSLL) Revenue and EPS Prognostications

Simply Wall St·11/20/2026 00:01:23
Listen to the news

Today is shaping up negative for Jeena Sikho Lifecare Limited (NSE:JSLL) shareholders, with the covering analyst delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analyst has soured majorly on the business.

Following the downgrade, the latest consensus from Jeena Sikho Lifecare's solo analyst is for revenues of ₹9.6b in 2027, which would reflect an okay 7.0% improvement in sales compared to the last 12 months. Statutory earnings per share are supposed to decrease 7.8% to ₹15.90 in the same period. Before this latest update, the analyst had been forecasting revenues of ₹11b and earnings per share (EPS) of ₹25.10 in 2027. It looks like analyst sentiment has declined substantially, with a measurable cut to revenue estimates and a large cut to earnings per share numbers as well.

Check out our latest analysis for Jeena Sikho Lifecare

earnings-and-revenue-growth
NSEI:JSLL Earnings and Revenue Growth November 20th 2026

It'll come as no surprise then, to learn that the analyst has cut their price target 56% to ₹440.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Jeena Sikho Lifecare's revenue growth is expected to slow, with the forecast 14% annualised growth rate until the end of 2027 being well below the historical 42% p.a. growth over the last three years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 18% per year. Factoring in the forecast slowdown in growth, it seems obvious that Jeena Sikho Lifecare is also expected to grow slower than other industry participants.

The Bottom Line

The most important thing to take away is that the analyst cut their earnings per share estimates, expecting a clear decline in business conditions. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. After such a stark change in sentiment from the analyst, we'd understand if readers now felt a bit wary of Jeena Sikho Lifecare.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At least one analyst has provided forecasts out to 2029, which can be seen for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.